The role of soluble factors in MSC-mediated immunoregulation

It is known that the immunomodulatory functions of mesenchymal stem cells (MSCs) are realized through interdependent immunoregulatory network. Recently, researchers have increasingly been searching for soluble factors and molecules secreted in immunoprivileged organs and tissues and allowing to avoid the immune response. Such molecules can be galectin-1 and HLAG, which expressed on the trophoblast and ensure the development of immunotolerance.
The objective of this study was a comparative analysis of the production of soluble HLA-G and galectin-1 molecules, as well as interleukin-10 by intact mesenchymal stem cells and during their co-cultivation with peripheral blood lymphocytes of recipients of allogeneic hematopoietic stem cells.
As a result of the study, it was found that for the release of the soluble form of HLA-G and, consequently, the implementation of the immunomodulatory properties of MSCs, interaction between MSCs and peripheral blood lymphocytes is necessary. At the same time, the intercellular interaction of MSCs and lymphocytes did not promote increased production of galectin-1, the main contribution to the production of which in mixed cultures was made by MSCs. The level of soluble HLA-G molecule depended on the concentration of IL-10 in the culture. The revealed patterns indicate that the choice of a biomedical cell product based on MSCs should be carried out taking into account the production of soluble factors characterizing their immunoregulatory potential, which can ultimately increase the effectiveness of cell therapy.

1. Q. Zhang, L. Fu, Y. Liang, Exosomes originating from MSCs stimulated with TGF-β and IFN-γ promote Treg differentiation, J Cell Physiol, 2018, no. 233, pp. 6832–6840.

2. A. Del Fattore, R. Luciano, L. Pascucci, Immunoregulatory effects of Mesenchymal Stem Cell-derived Extracellular Vesicles on T lymphocytes, Cell Transplant, 2015, no. 24, pp. 2615-2627.

3. S. Aggarwal, M.F. Pittenger, Human mesenchymal stem cells modulate allogeneic immune cell responses, Blood, 2005, no. 105, pp. 1815–1822.

4. G. Ren, L. Zhang, X. Zhao, Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide, Cell Stem Cell, 2008, no. 2, pp. 141–150.

5. A. Hammer, Immunological regulation of trophoblast invasion, J Reprod Immunol, 2011, no. 90, pp. 21–28.

6. M. Sioud, New Insights into Mesenchymal Stromal Cell-Mediated T-Cell Suppression Through Galectins, Scandinavian Journal of Immunology, 2011, no. 73, pp. 79–84.

7. S. Fournel, M. Aguerre-Girr, X. Huc, Cutting edge: Soluble HLAG1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8, J Immunol, 2000, no. 164, pp. 6100–6104.

8. S. Gregori, D. Tomasoni, V. Pacciani, Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10 dependent ILT4/HLA-G pathway, Blood, 2010, no. 116, pp. 935–944.

9. V.D. Jakushina, O.A. Vasil'eva, N.V. Rjazanceva, Galectin-1: role in the formation of characteristics of innate and acquired immunity [Galektin-1: rol' v formirovanii osobennostej vrozhdennogo i priobretennogo immuniteta], Medical Immunology (Medicinskaja immunologija), 2012, no. 14, pp. 21-32.

10. L.G. Baum, D.P. Blackall, S. Arias-Magallano, Amelioration of graft versus host disease by galectin-1, Clin Immunol, 2003, no. 109, pp. 295–307.

11. A. Boyum, Separation of blood leukocytes, granulocytes and lymphocytes, Tissue antigens, 1974, no. 4, pp. 269-274.

12. S.I. Krivenko, E.S. Buzuk, N.I. Dedjulja, E.A. Selezneva, E.A. Nazarova, A.A. Koritko, Patent BY 18051, MPK C12N 5/0775. Sposob vydelenija mezenhimal'nyh stvolovyh kletok [Method for isolating mesenchymal stem cells], №20101863, application 21.12.2010, published 28.02.2014:6 p.

13. A. Nasef, N. Mathieu, A. Chapel, Immunosuppressive effects of mesenchymal stem cells: Involvement of HLA-G, Transplantation, 2007, no. 84, pp. 231–237.

14. R. Rizzo, D. Campioni, M. Stignani, A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells, Cytotherapy, 2008, no.10, pp. 364 – 375.

15. D. Lysák, L. Koutová, M. Holubová, The Quality Control of Mesenchymal Stromal Cells by in Vitro Testing of Their Immunomodulatory Effect on Allogeneic Lymphocytes, Folia Biologica, 2016, no. 62, pp. 120-130.

16.